233 related articles for article (PubMed ID: 22223883)
1. The induction of a nucleoplasmic reticulum by prelamin A accumulation requires CTP:phosphocholine cytidylyltransferase-α.
Goulbourne CN; Malhas AN; Vaux DJ
J Cell Sci; 2011 Dec; 124(Pt 24):4253-66. PubMed ID: 22223883
[TBL] [Abstract][Full Text] [Related]
2. Expansion of the nucleoplasmic reticulum requires the coordinated activity of lamins and CTP:phosphocholine cytidylyltransferase alpha.
Gehrig K; Cornell RB; Ridgway ND
Mol Biol Cell; 2008 Jan; 19(1):237-47. PubMed ID: 17959832
[TBL] [Abstract][Full Text] [Related]
3. CTP:phosphocholine cytidylyltransferase α (CCTα) and lamins alter nuclear membrane structure without affecting phosphatidylcholine synthesis.
Gehrig K; Ridgway ND
Biochim Biophys Acta; 2011 Jun; 1811(6):377-85. PubMed ID: 21504799
[TBL] [Abstract][Full Text] [Related]
4. Analysis of prelamin A biogenesis reveals the nucleus to be a CaaX processing compartment.
Barrowman J; Hamblet C; George CM; Michaelis S
Mol Biol Cell; 2008 Dec; 19(12):5398-408. PubMed ID: 18923140
[TBL] [Abstract][Full Text] [Related]
5. RNAi of FACE1 protease results in growth inhibition of human cells expressing lamin A: implications for Hutchinson-Gilford progeria syndrome.
Gruber J; Lampe T; Osborn M; Weber K
J Cell Sci; 2005 Feb; 118(Pt 4):689-96. PubMed ID: 15671064
[TBL] [Abstract][Full Text] [Related]
6. Different prelamin A forms accumulate in human fibroblasts: a study in experimental models and progeria.
Dominici S; Fiori V; Magnani M; Schena E; Capanni C; Camozzi D; D'Apice MR; Le Dour C; Auclair M; Caron M; Novelli G; Vigouroux C; Maraldi NM; Lattanzi G
Eur J Histochem; 2009; 53(1):43-52. PubMed ID: 19351612
[TBL] [Abstract][Full Text] [Related]
7. Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina.
Lutz RJ; Trujillo MA; Denham KS; Wenger L; Sinensky M
Proc Natl Acad Sci U S A; 1992 Apr; 89(7):3000-4. PubMed ID: 1557405
[TBL] [Abstract][Full Text] [Related]
8. HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
Coffinier C; Hudon SE; Farber EA; Chang SY; Hrycyna CA; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2007 Aug; 104(33):13432-7. PubMed ID: 17652517
[TBL] [Abstract][Full Text] [Related]
9. Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria.
Cenni V; Capanni C; Columbaro M; Ortolani M; D'Apice MR; Novelli G; Fini M; Marmiroli S; Scarano E; Maraldi NM; Squarzoni S; Prencipe S; Lattanzi G
Eur J Histochem; 2011 Oct; 55(4):e36. PubMed ID: 22297442
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of protein geranylgeranyltransferase-I lead to prelamin A accumulation in cells by inhibiting ZMPSTE24.
Chang SY; Hudon-Miller SE; Yang SH; Jung HJ; Lee JM; Farber E; Subramanian T; Andres DA; Spielmann HP; Hrycyna CA; Young SG; Fong LG
J Lipid Res; 2012 Jun; 53(6):1176-82. PubMed ID: 22448028
[TBL] [Abstract][Full Text] [Related]
11. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging.
Ragnauth CD; Warren DT; Liu Y; McNair R; Tajsic T; Figg N; Shroff R; Skepper J; Shanahan CM
Circulation; 2010 May; 121(20):2200-10. PubMed ID: 20458013
[TBL] [Abstract][Full Text] [Related]
12. Prelamin A farnesylation and progeroid syndromes.
Young SG; Meta M; Yang SH; Fong LG
J Biol Chem; 2006 Dec; 281(52):39741-5. PubMed ID: 17090536
[TBL] [Abstract][Full Text] [Related]
13. Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24.
Corrigan DP; Kuszczak D; Rusinol AE; Thewke DP; Hrycyna CA; Michaelis S; Sinensky MS
Biochem J; 2005 Apr; 387(Pt 1):129-38. PubMed ID: 15479156
[TBL] [Abstract][Full Text] [Related]
14. Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24.
Barrowman J; Hamblet C; Kane MS; Michaelis S
PLoS One; 2012; 7(2):e32120. PubMed ID: 22355414
[TBL] [Abstract][Full Text] [Related]
15. HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy?
Goulbourne CN; Vaux DJ
Biochem Soc Trans; 2010 Feb; 38(Pt 1):292-6. PubMed ID: 20074077
[TBL] [Abstract][Full Text] [Related]
16. A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
Coffinier C; Hudon SE; Lee R; Farber EA; Nobumori C; Miner JH; Andres DA; Spielmann HP; Hrycyna CA; Fong LG; Young SG
J Biol Chem; 2008 Apr; 283(15):9797-804. PubMed ID: 18230615
[TBL] [Abstract][Full Text] [Related]
17. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes.
Toth JI; Yang SH; Qiao X; Beigneux AP; Gelb MH; Moulson CL; Miner JH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12873-8. PubMed ID: 16129834
[TBL] [Abstract][Full Text] [Related]
18. Prelamin A-mediated recruitment of SUN1 to the nuclear envelope directs nuclear positioning in human muscle.
Mattioli E; Columbaro M; Capanni C; Maraldi NM; Cenni V; Scotlandi K; Marino MT; Merlini L; Squarzoni S; Lattanzi G
Cell Death Differ; 2011 Aug; 18(8):1305-15. PubMed ID: 21311568
[TBL] [Abstract][Full Text] [Related]
19. Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins.
Wang Y; Ostlund C; Choi JC; Swayne TC; Gundersen GG; Worman HJ
Nucleus; 2012; 3(5):452-62. PubMed ID: 22895092
[TBL] [Abstract][Full Text] [Related]
20. Drugs affecting prelamin A processing: effects on heterochromatin organization.
Mattioli E; Columbaro M; Capanni C; Santi S; Maraldi NM; D'Apice MR; Novelli G; Riccio M; Squarzoni S; Foisner R; Lattanzi G
Exp Cell Res; 2008 Feb; 314(3):453-62. PubMed ID: 18093584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
